Drug intelligence / Profile preview

Afluria Quad

Development stage
Approved
Lead developer
CSL Seqirus
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Afluria Quad is a quadrivalent inactivated influenza vaccine used for the prevention of influenza caused by the virus subtypes and types (A and B) contained in the vaccine. It contains purified hemagglutinin antigens from four different strains of influenza virus, selected annually based on recommendations to match circulating strains. The vaccine works by stimulating an immune response that leads to the production of antibodies against these viral antigens, providing protection against infection. It is administered as an intramuscular injection and is indicated for use in individuals 6 months of age and older (in some regions, only for those 5 years and older). Annual vaccination is recommended due to frequent changes in circulating influenza strains. The product is developed and manufactured by Seqirus.

Brand names
Afluria Quad
Other names
Afluria QuadrivalentAfluria Quadrivalent Southern Hemisphere
02

Targets

Influenza virus hemagglutinin receptor-binding domainHA (Hemagglutinin)

Beyond the preview

Go deeper on Afluria Quad.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Afluria Quad.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call